The treated group had a higher overall risk of comorbidity, whereas the non-supplemented group had lower values of O2 saturation at admission, higher CURB-65 score and higher rate of ARDS moderate or severe, higher levels of inflammatory markers such as CRP, and a higher frequency of kidney failure. The gene discussed is CRP; the disease is acute respiratory distress syndrome.